Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
DIANT Pharma
company
About
DIANT Pharma develops continuous processing technology for nanoparticle drug products and vaccines.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $256K
- Industries
- Biopharma,Biotechnology,Nanotechnology
- Founded date
- Jan 1, 2019
- Number Of Employee
- 11 - 50
- Operating Status
- Active
DIANT Pharma develops continuous processing technology for nanoparticle drug products and vaccines. They utilize a proprietary and continuous ethanol-injection system to form nanoparticles with controlled particle sizes at high flow rates, providing pharmaceutical companies with a continuous drug encapsulation technique to achieve their goals and high encapsulation processes.Founded in 2019, DIANT offers technology that is robust and reliable from R&D to manufacturing over a product’s lifespan.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$256K
DIANT Pharma has raised a total of
$256K
in funding over 2 rounds. Their latest funding was raised on
Feb 9, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 9, 2022 | Grant | $256K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
DIANT Pharma is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
